<DOC>
	<DOCNO>NCT02668276</DOCNO>
	<brief_summary>This research do well understand new lab test call Oncotype DX Prostate Cancer Assay may impact treatment men decide get feel think choice treatment . The study compare men receive new lab test men receive usual counseling give men get new diagnosis prostate cancer . Prostate cancer sometimes slow-growing sometimes fast-growing . Healthcare provider search good way predict tumor behave man make good decision receive treatment . The Oncotype DX lab test use leftover prostate biopsy tissue generate Genomic Prostate Score ( GPS ) . The GPS relate risk fast-growing cancer discover surgery perform remove man 's prostate . The goal study find test help men decide prostate cancer treat . Treatment option include surgery remove prostate , radiation therapy , approach call `` active surveillance '' immediate therapy tumor watch use prostate specific antigen ( PSA ) test repeat biopsy .</brief_summary>
	<brief_title>Engaging Newly Diagnosed Men About Cancer Treatment Options</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men newly diagnose prostate cancer categorize Very Low , Low , Intermediate risk NCCN criterion ; Are age 76 young Men categorize High Very High risk NCCN criterion ; Men already receive counsel urologist treatment option decide undergo treatment , active surveillance , watchful waiting ; Men age 77 older</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostatic neoplasm</keyword>
	<keyword>Oncotype DX</keyword>
	<keyword>Treatment Decisions</keyword>
</DOC>